NetraMark to Present AI-Powered Clinical Trial Analysis Tools for Psychiatric Disorders at ISCTM Meeting
核心洞察
NetraMark (搜索) will showcase novel AI-based tools that demonstrate 28% improved accuracy in predicting treatment responses for major depressive disorder (搜索) clinical trials at the ISCTM Annual Meeting.
The company's NetraAI (搜索) technology successfully identified distinct patient subpopulations in the CATIE schizophrenia (搜索) trial, enabling better characterization of drug responses to olanzapine and perphenazine.
The proprietary machine learning approach features unique focus mechanisms that separate datasets into explainable subsets, potentially transforming CNS clinical trial design and analysis.
NetraMark (搜索) Holdings Inc. is set to present groundbreaking data demonstrating the capabilities of its AI-powered clinical trial analytics tools at the International Society for CNS Clinical Trials and Methodology (ISCTM) 21st Annual Scientific Meeting, taking place February 19-21, 2025, in Washington, DC.
Advancing Depression Treatment Through AI Analytics
The company's Chief Medical Officer, Dr. Larry Alphs, will present findings showing how their mathematically augmented machine learning tools have achieved significant improvements in patient stratification for psychiatric clinical trials. Most notably, their approach has demonstrated a 28% increase in model accuracy for predicting treatment responses in major depressive disorder (搜索) (MDD) studies.
"This innovative AI-driven approach has the potential to transform the way CNS clinical trials are designed and analyzed," stated Dr. Alphs. "By harnessing the power of advanced ML, NetraAI (搜索) can deconstruct heterogenous patient populations into actionable subgroups, leading to more accurate predictions with the opportunity to identify more effective treatments for patients with psychiatric disorders."
Breakthrough in Schizophrenia Trial Analysis
A second presentation will focus on the application of NetraAI (搜索) to the CATIE schizophrenia (搜索) trial, where the technology successfully identified clinically meaningful subpopulations characterizing responses to olanzapine and perphenazine. This achievement is particularly significant given the historical challenges in managing patient heterogeneity in schizophrenia studies.
NetraAI's Distinctive Technological Approach
What sets NetraAI (搜索) apart from conventional AI methods is its unique engineering featuring focus mechanisms that effectively separate small datasets into explainable and unexplainable subsets. This capability is crucial for avoiding the common pitfall of "overfitting" in clinical trial data analysis, which can obscure important information needed for trial success.
The system's topology-based algorithm can parse patient data into subsets of strongly related individuals across multiple variables simultaneously. This allows for more precise disease segmentation and accurate classification of patient responses to treatments, even with smaller datasets that typically challenge traditional AI approaches.
Clinical Trial Implementation
The technology has demonstrated enhanced specificity, sensitivity, and AUC scores in clinical applications. For CNS disorder trials, which have historically struggled with patient heterogeneity, NetraAI (搜索)'s approach offers a promising solution for improving trial design and outcome prediction.
The company's presentations at ISCTM will include detailed analyses of both MDD and schizophrenia (搜索) studies, showcasing the practical applications of their AI-driven approach in real-world clinical settings. These findings represent a significant step forward in the use of artificial intelligence to advance psychiatric drug development and patient care.